Form 4: Sage Therapeutics Executive Michael Quirk Reports Stock and Option Awards

Michael Quirk, Chief Scientific Officer and Interim Head of R&D at Sage Therapeutics, reports the acquisition of stock and option awards.

Summary

• Michael C. Quirk, Chief Scientific Officer and Interim Head of R&D at Sage Therapeutics, filed a Form 4 on April 2, 2025, reporting transactions related to Sage Therapeutics, Inc. [SAGE] stock.
• On April 1, 2025, Quirk acquired 2,000 shares of common stock through restricted stock units (RSUs) under the 2024 Equity Incentive Plan at $0.00.
• These RSUs vest in equal annual installments over four years, starting April 1, 2026, contingent upon continued service.
• Additionally, Quirk acquired an option to purchase 4,000 shares of common stock on April 1, 2025, also under the 2024 Equity Incentive Plan.
• The option shares vest over four years, with 25% vesting on April 1, 2026, and the remainder vesting in equal monthly installments thereafter, subject to continued service.
• The exercise price of the option is $0.00, and it expires on March 31, 2035.
• Following these transactions, Quirk beneficially owns 29,108 shares of common stock and options for 4,000 shares.

Sentiment

Score: 6

Explanation: The sentiment is neutral. It's a routine disclosure of stock and option awards, which is neither particularly positive nor negative on its own. The vesting schedule implies a degree of confidence in the executive's continued contribution.

Positives

• The granting of RSUs and stock options to a key executive like Michael Quirk can be seen as a positive sign, aligning his interests with the company's long-term success.
• The vesting schedules encourage continued service and commitment from the executive.

Future Outlook

The document does not contain specific forward-looking statements about the company's overall performance, but the vesting schedules of the RSUs and stock options suggest an expectation of continued service from the executive.

Industry Context

This type of filing is standard for publicly traded companies and reflects the ongoing compensation and equity ownership adjustments for key executives. It's common practice to use stock options and RSUs to incentivize and retain talent in the biotech industry.

Comparison to Industry Standards

• Equity compensation is a standard practice in the biotechnology industry to attract and retain talent.
• Companies like Amgen, Gilead, and Biogen routinely grant stock options and RSUs to their executives.
• The vesting schedules described in the document are typical, with vesting occurring over a period of several years to incentivize long-term commitment.

Stakeholder Impact

• The granting of equity to executives can align their interests with those of shareholders, potentially leading to better company performance.
• Employees may view equity grants as a positive sign of the company's commitment to its leadership.

Key Dates

Keywords

Form 4, Sage Therapeutics, Michael Quirk, stock options, RSUs, beneficial ownership, equity incentive plan, vesting